BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37012831)

  • 1. Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis.
    Yi Q; Liu C; Cui Y; Yang Y; Li Y; Fan X; Wu K
    Cancer Med; 2023 Mar; 12(6):6477-6487. PubMed ID: 37012831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.
    Jiang L; Zhu J; Chen X; Wang Y; Wu L; Wan G; Han Y; Leng X; Peng L; Wang Q
    Radiat Oncol; 2022 Dec; 17(1):218. PubMed ID: 36585731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
    Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J
    Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
    Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
    Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
    Chen Y; Ye J; Zhu Z; Zhao W; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Jia H; Lu S; Zhang Z; Zhao K
    J Clin Oncol; 2019 Jul; 37(20):1695-1703. PubMed ID: 30920880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
    Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
    JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.
    Zeng J; Cui X; Cheng L; Chen Y; Du X; Sheng L
    Cancer Radiother; 2021 Jul; 25(5):441-446. PubMed ID: 33958272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
    Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
    Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
    Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
    Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of cisplatin and nanoparticle albumin-bound-paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma.
    Jiang H; Li Q; Chen B; Xi M; Makelike K; Liu S; Hu Y; Zhu Y
    Cancer Med; 2023 Jul; 12(14):15187-15198. PubMed ID: 37334881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Huang TC; Lin CC; Wu YC; Chia-Hsien Cheng J; Lee JM; Wang HP; Huang PM; Hsu FM; Yeh KH; Cheng AL; Tzen KY; Hsu CH
    J Formos Med Assoc; 2019 Jun; 118(6):1024-1030. PubMed ID: 30502100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
    Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
    Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
    Zhao C; Lin L; Liu J; Liu R; Chen Y; Ge F; Jia R; Jin Y; Wang Y; Xu J
    Oncotarget; 2016 Aug; 7(35):57310-57316. PubMed ID: 28087951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
    Wang W; Yi Y; Jia Y; Dong X; Zhang J; Song X; Song Y
    Thorac Cancer; 2022 Mar; 13(6):824-831. PubMed ID: 35118824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
    Fang M; Song T; Liang X; Lv S; Li J; Xu H; Luo L; Jia Y
    Oncotarget; 2017 Jun; 8(23):37080-37090. PubMed ID: 28415745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma.
    Fan Y; Jiang Y; Zhou X; Chen Q; Huang Z; Xu Y; Gong L; Yu H; Yang H; Liu J; Lei T; Zhao Q; Mao W
    Oncotarget; 2016 Aug; 7(31):50624-50634. PubMed ID: 27244882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin.
    Yada M; Yamamoto S; Honma Y; Hirano H; Okita N; Shoji H; Iwasa S; Takashima A; Nagahara A; Kato K
    In Vivo; 2024; 38(2):761-766. PubMed ID: 38418117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial.
    Wang Z; Hu M; Hu Y; Li Q; Wu J; Fong WP; Ren C; Wang D; Tan Q; Yang H; Li Y
    Esophagus; 2022 Jan; 19(1):120-128. PubMed ID: 34319435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.